Enter your email address below and subscribe to our newsletter

Innovation

Share your love

The potential of AI in retina with Daniela Ferrara

This conversation features Daniella Ferrara, Chief Medical Officer for TopCon Healthcare, discussing the transformative potential of artificial intelligence in retinal imaging and ophthalmology. Ferrara, an ophthalmologist and retina specialist with 25 years of experience in retinal imaging innovation. The discussion…

What is optical coherence tomography

Optical coherence tomography (OCT) has been a cornerstone tool for many years for the diagnosis and management of conditions involving the posterior segment. Although continuous hardware and software advances have increased the applications and utility of OCT, multimodal imaging that…

A Next-Gen Monofocal IOL From Johnson & Johnson Vision

Johnson & Johnson Vision Announces Launch of TECNIS Eyhance™ Toric II IOL with TECNIS Simplicity™ Delivery System, a Next-Generation Monofocal Intraocular Lens for Cataracts Patients with Astigmatism, in Europe TECNIS Eyhance™ Toric II IOL offers all the benefits associated with…

J&J announced new products at the AAO annual meeting

Johnson & Johnson Vision announced a series of new products and innovations at the 2019 American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco, CA, USA. The company announced the US Food & Drug Administration (FDA) approval of the…

VSY Biotech Signs Agreement With WAKAMOTO Pharma

Leinfelden – Echterdingen, Germany March 19, 2021, ­ VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics, announced today an agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. (hereinafter refer to…

HealthCare Royalty And Clearside Bio to Enter Into Agreement

Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. The money received from the deal will be put to use by Clearside to fund the ongoing clinical testing…

Rayner’s RayOne EMV IOL Approved By FDA I OBN

Since producing the first IOL in the world in 1949, Rayner has led the way in innovation, focusing on giving you and your patients the best IOLs and opthalmic solutions while always being guided by research to enhance patient outcomes…

Stay informed and not overwhelmed, subscribe now!